Director R. Scott Huennekens filed a Form 4 with the SEC on November 18, 2026, disclosing the purchase of 12,500 shares of NeuroPace Inc common stock through the Front Foot Trust on that same date.
Key Highlights
- Shares acquired: 12,500 shares of NeuroPace Inc common stock were purchased on November 18, 2026.
- Weighted average price: The reported per-share price was $8.2929, a weighted average across multiple transactions.
- Price range: Individual transactions occurred at prices ranging from $8.2350 to $8.3657, inclusive, according to the filing.
- Beneficial ownership following transaction: The filing reports 12,500 shares beneficially owned following the transaction, held indirectly by the Front Foot Trust.
- Rule 10b-18 compliance: The filing states purchases were made in compliance with SEC Rule 10b-18 safe harbor restrictions for manner, timing, price, and volume of purchase.
- Reporting person role: Huennekens is identified as a Director of NeuroPace Inc (NASDAQ:NPCE).
NeuroPace Director Huennekens Acquires Common Stock Through Front Foot Trust
According to the Form 4 filed with the SEC, R. Scott Huennekens, a director of NeuroPace Inc, acquired 12,500 shares of the company's common stock on November 18, 2026. The transaction is coded "P" (purchase) and designated as acquired ("A"). The shares were purchased indirectly through an entity identified as the Front Foot Trust, in which Huennekens and a member of his immediate family serve as trustees.
The filing reports a weighted average purchase price of $8.2929 per share. The shares were purchased across multiple transactions, with individual prices ranging from $8.2350 to $8.3657, inclusive. The filing notes that Huennekens "undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4."
The filing also states that the purchases were made "in compliance with SEC Rule 10b-18 safe harbor restrictions for manner, timing, price, and volume of purchase" and that they "complied with broker-dealer and issuer pre-clearance procedures." Regarding beneficial ownership, the filing includes a disclaimer noting that Huennekens "disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein." The Form 4 was signed by Leah Akin as Attorney-in-Fact on November 18, 2026.
What Was Disclosed
NeuroPace Inc director R. Scott Huennekens disclosed the acquisition of 12,500 shares of common stock at a weighted average price of $8.2929, purchased indirectly through the Front Foot Trust on November 18, 2026, with the transaction reported as Rule 10b-18 compliant.




Please wait processing your request...